Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced…

By Christopher Ireson, S. Orr, Donald J. L. Jones, Richard Verschoyle, C. Lim, Jin-Li Luo, Lynne M. Howells, S. Plummer, R. Jukes, Marion L. Williams and 2 more. Cancer Research, 2001

636 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/8bc8d3fd4e7220efac4311d9eddf97da3669a605

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Biological Properties of Curcumin-Cellular and Molecular Mechanisms of Action (2004, background): “∗Less bioactive compared to curcumin in terms of the inhibitory effect on PGE2 formation (Ireson et al., 2001).”
Curcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials (2008, unknown): “These drug concentrations were less than one hundredth of the concentrations of curcumin that have been shown in vitro to have an effect on this pathway in blood or colon cells (113, 195).”
Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease (2008, background): “Pharmacokinetic studies of curcumin demonstrate extensive intestinal sulfation and glucuronidation (Kelloff et al., 1996; Pan et al., 1999; Ireson et al., 2001; Sharma et al., 2004).”
Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. (2007, background): “In rodents, curcumin ndergoes avid metabolism by conjugation and reduction and its bsorption after oral dosing is characterized by poor systemic ioavailability (Holder et al., 1978; Wahlstrom and Blennow, 978; Ireson et al., 2001; Sharma et al., 2001a,b).”
Bioactivity of dietary polyphenols: The role of metabolites (2020, background): “Glucuronidation of curcumin is catalyzed by UGTs in the intestinal and hepatic microsomes (Ireson et al. 2001, 2002).”
Curcumin as "Curecumin": from kitchen to clinic. (2008, background): “[154] Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, et al.”
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer (2008, background): “It is now well established that curcumin exists in rodent and human plasma largely in conjugated forms, with the glucuronide conjugate present in much greater abundance than the sulfate conjugate ( 32 ).”
Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. (2002, methodology): “HPLC conditions used for the on-line HPLC-mass spectrometric analyses were as described before (18).”
Phase I Clinical Trial of Oral Curcumin (2004, methodology): “This phenomenon was also observed in human-derived colon cells cultured in vitro, and inhibition was demonstrated to be the corollary, at least in part, of the inhibition of the nuclear factor-B–activating enzymes IKK-/ by curcumin (10, 15 ).”